Enhanced expression of NGF receptors in multiple sclerosis lesions.

نویسندگان

  • Paola Valdo
  • Chiara Stegagno
  • Sara Mazzucco
  • Elisa Zuliani
  • GianLuigi Zanusso
  • Giuseppe Moretto
  • Cedric S Raine
  • Bruno Bonetti
چکیده

The receptor for nerve growth factor (NGF) comprises a 75-kDa (NGFRp75) and a tyrosine kinase A (TrkA) subunit. In view of conflicting opinions on the identity of glial targets of NGF in human central nervous system (CNS), we examined the cellular distribution of both NGF receptor subunits in normal CNS and in chronic multiple sclerosis (MS) lesions. For this, we compared the pattern of recognition of 2 monoclonal antibodies (mAbs) and a polyclonal antiserum to NGFRp75. Only the 2 mAbs specifically recognized NGFRp75, while the polyclonal antiserum showed widespread reactivity. In normal CNS and silent MS lesions, immunohistochemistry with anti-NGFRp75 mAbs and for TrkA revealed perivascular cell reactivity. At the edge of chronic active MS lesions, selective NGFRp75 staining was prominent on reactive astrocytes, while throughout the lesion, NGFRp75 was expressed on microglia/macrophages. The vast majority of mature or precursor oligodendrocytes did not express NGFRp75. Both NGF receptors were co-expressed on a subset of inflammatory cells. Immunoreactivity for NGFRp75 on glial and immune cells did not correlate with the distribution of apoptotic figures, as detected by TUNEL. Thus, expression of NGF receptors in active MS lesions suggests a role for NGF in regulating the autoimmune response at both immune and glial cell levels.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Expression of Chemokine Receptors on Th1/Th2 CD4+ Lymphocytes in Patients with Multiple Sclerosis

Background: Th1 cells preferentially express CXCR3, CCR5 and CCR6, while CCR3 and CCR4 are predominantly expressed by Th2 cell subsets. Multiple Sclerosis (MS) is a Th1 cell-dependant chronic inflammatory disease of the central nervous system, and immunomudolatory cytokines could alter the chemokine expression pattern of these lymphocyte subsets. Objective: This study was performed to measure c...

متن کامل

Tumefactive: A Rare First presentation of Multiple Sclerosis

Tumefactive demyelinating lesions are a rare presentation of multiple sclerosis (MS). Diagnosis of tumefactive is commonly carried out using magnetic resonance image (MRI). Tumefactive diagnosis is difficult because of may similar to the clinical and MRI characteristics of glioma or a cerebral abscess. We presented a 35-years-old female with one episode of secondary generalized seizure after de...

متن کامل

Quantification of blood-brain-barrier permeability dysregulation and inflammatory activity in MS lesions by dynamic-contrast enhanced MR imaging

Objective: Measurement of blood-brain permeability dysfunction in active and chronic MS lesions with T1-weighted dynamic contrast-enhanced MRI to show variation in inflammatory activity Background: blood-brain-barrier perfusion characterization impaired in MS as some studies have shown recently buta comparison between perfusion parameters in contrast-enhanced and non-enhanced lesions not have ...

متن کامل

The Effect of one Course of Swimming Exercise before Induction of Multiple Sclerosis (MS) on Nerve Growth Factor Levels in Rat’s Brain

Background and Aim: Multiple Sclerosis is a chronic inflammatory disease with unknown etiology in the nervous system. However, exercise routinely for these patients is beneficial, but the effect of pretreatment swimming exercise in this disease has not been fixed. Therefore, the aim of these study was to investigate pretreatment effect of swimming exercise on NGF levels in female Lewis rats wit...

متن کامل

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis

Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of neuropathology and experimental neurology

دوره 61 1  شماره 

صفحات  -

تاریخ انتشار 2002